Amicus is designed to fully replace multinationals’ subsidiaries in those countries that the multinational chooses not to enter, or to exit.
Amicus is dedicated to service of research-based pharmaceutical and healthcare companies who choose to enter the Balkans and the Baltics in partnership, and not entirely with their own subsidiaries. The company is staffed by a unique group of skilled managers and medical professionals who are dedicated to bring modern medicines to the people of our two regions. We are a service-oriented, high quality and ethically-driven company.
15.12.2025
SK Capital acquires majority stake in Swixx Biopharma at EUR 1.5 billion valuation (startupticker.ch)
24.05.2024
Following a strategic acquisition, Swixx BioPharma expects a turnover exceeding one billion (startupticker.ch)
21.05.2021
Swixx BioPharma secures close to €100 million to fuel its growth (startupticker.ch)
28.04.2017
HBM invests EUR 20 million in Amicus (startupticker.ch)
28.04.2017
HBM invests EUR 20 million in Amicus (startupticker.ch)
No milestones
No Jobs
No videos and documents
No Awards